Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other 1Gastrointestinal 1

Conditions

Multiple Myeloma 61Neoplasms 7Neoplasms, Plasma Cell 6Recurrence 5Hematologic Neoplasms 4Renal Insufficiency 3Paraproteinemias 3Lymphoma 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Blood Protein Disorders 2Purpura 1Prostatic Neoplasms 1Neoplasm, Residual 1Nausea 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Macroglossia 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphadenopathy 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1

Interventions

Dexamethasone 38Aprepitant 31Ondansetron 27Palonosetron 25Granisetron 16Calcium Dobesilate 15Olanzapine 12Therapeutics 8dexamethasone acetate 7Cyclophosphamide 7fosaprepitant 6casopitant 6Doxorubicin 6Radiotherapy 5netupitant 4dolasetron 4dexamethasone 21-phosphate 4Vincristine 4Tropisetron 4Metoclopramide 4Acupressure 4Yoga 3Psychiatric Rehabilitation 3Prochlorperazine 3Lorazepam 3Electroacupuncture 3Dronabinol 3Cisplatin 3Analgesia 3peppermint oil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nausea × isatuximab × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡